Anti-Xa Activity in Elderly Xabans-Treated Patients With Atrial Fibrillation

Am J Ther. 2020 Sep/Oct;27(5):e507-e509. doi: 10.1097/MJT.0000000000001014.
No abstract available

Publication types

  • Letter
  • Observational Study

MeSH terms

  • Age Factors
  • Aged
  • Aged, 80 and over
  • Atrial Fibrillation / blood
  • Atrial Fibrillation / drug therapy*
  • Drug Administration Schedule
  • Factor Xa Inhibitors / administration & dosage
  • Factor Xa Inhibitors / pharmacokinetics*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pilot Projects
  • Product Surveillance, Postmarketing / statistics & numerical data
  • Prospective Studies
  • Pyrazoles / administration & dosage
  • Pyrazoles / pharmacokinetics
  • Pyridones / administration & dosage
  • Pyridones / pharmacokinetics
  • Rivaroxaban / administration & dosage
  • Rivaroxaban / pharmacokinetics
  • Time Factors

Substances

  • Factor Xa Inhibitors
  • Pyrazoles
  • Pyridones
  • apixaban
  • Rivaroxaban